Elsevier

Annals of Oncology

Volume 25, Issue 9, September 2014, Pages 1681-1690
Annals of Oncology

special article
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

https://doi.org/10.1093/annonc/mdu145Get rights and content
Under an Elsevier user license
open archive

ABSTRACT

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11–12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

Key words

ESMO
consensus
non-small-cell lung cancer
pathology
molecular testing
recommendations

Cited by (0)

See the Appendix for Panel Members.